Objective: Either GLP-1RA or SGLT2i is recommended to use in people with type 2 diabetes (T2D) with CKD. Whether these drugs jointly work for reno-protection are not well known. We evaluated add-on effects of GLP-1RA (liraglutide 95%) in Japanese people with T2D treated by SGLT2i by assessing individual eGFR trajectory.

Methods: A total of 75 persons with T2D (CKD stage 3-4), treated by SGLT2i (empagliflozin 65%) were analyzed. At the time of recruitment, average age was 70.3±12.2 yr-old, the duration of diabetes was 15.4±10.1 yrs, and macroalbuminuria (Macro-Alb) existed in 49% (37/75). To trace the eGFR trajectory in each person, most rapid eGFR slope was calculated individually from the data for 46±20 months before using SGLT2i and 46±16 months after adding it. GLP-1RA was initially or additionally used in 53%.

Results: 1) Proportion of responders (defined as their ratios of slopes are reduced > 1.0 after addition of SGLT2i) in each stage were as follows: stage 3a; (21/29), stage 3b; (21/28), stage 4; (16/18). Slopes in responders (58/75) were improved as follows, -7.8±9.9 to -0.8±3.0ml/min/1.73m2/year (P<0.001) with GLP-1RA use in 52%. Slopes in non-responders (17/75) were worsened as follows, -1.8±1.9 to -3.6±3.1ml/min/1.73m2/year (P<0.001), despite GLP-1RA use in 59%. Macro-Alb was observed in 53% and 35%, respectively. 2) Slopes in rapid decliners (defined as most rapid individual eGFR slope greater than -10.0ml/min/1.73m2/y) (13/75) were improved from -18.9±16.4 to -1.3±3.3ml/min/1.73m2/year (P<0.01) by combined use of GLP-1RA in 85% (11/13). Macro-Alb existed in 69% (9/13) and nephrosis in 54% (7/13). 3) Sub-analysis (one of different GLP-1RA initiation regimes): Baseline slopes -16.7±19.8 were improved to -5.0±5.8 (P<0.05) by adding GLP-1RA, then to -2.7±3.8 ml/min/1.73m2/year (vs baseline: P<0.03) by adding SGLT2i. (n=11) Macro-Alb highly existed in 82% (9/11) and nephrosis in 46% (5/11).

Conclusion: GLP-1RA should be used with SGLT2i in rapid eGFR decliners or persons with Macro-Alb.

Disclosure

K.Kashima: None. H.Shimizu: None. M.Yamada: None.

© 2023 by the American Diabetes Association
2023
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.